Institut Curie;ABIVAX;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;Université Montpellier
发明人:
申请号：
EP15305277.4
公开号：
EP3058940A1
申请日:
2015.02.23
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present invention relates to A quinoline derivative of formula (I)or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites,for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient； and then terminating said treatment when: the viral load is low or undetectable； and/or the level of CD4+ cell count is maintained or restored.The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.
